{
  "metadata": {
    "enrichment_date": "2025-07-03T20:42:35.925271",
    "version": "1.0",
    "description": "Ontologically enriched pharmaceutical pipeline data with semantic annotations",
    "base_data_source": "/Users/necibea/Documents/GitHub/HCLS_Agents_Toolkit/amazon-bedrock-agents-healthcare-lifesciences/agents_catalog/23-data-harmonisation-drug-dev-pipeline/pipeline_data/harmonized_pipeline_data.json",
    "ontologies_used": [
      {
        "name": "MONDO",
        "full_name": "Monarch Disease Ontology",
        "url": "https://mondo.monarchinitiative.org/",
        "description": "Comprehensive disease ontology"
      },
      {
        "name": "ChEBI",
        "full_name": "Chemical Entities of Biological Interest",
        "url": "https://www.ebi.ac.uk/chebi/",
        "description": "Chemical ontology for biological entities"
      },
      {
        "name": "EFO",
        "full_name": "Experimental Factor Ontology",
        "url": "https://www.ebi.ac.uk/efo/",
        "description": "Ontology for experimental variables"
      },
      {
        "name": "NCIT",
        "full_name": "NCI Thesaurus",
        "url": "https://ncithesaurus.nci.nih.gov/",
        "description": "Cancer and biomedical terminology"
      },
      {
        "name": "MeSH",
        "full_name": "Medical Subject Headings",
        "url": "https://www.nlm.nih.gov/mesh/",
        "description": "Medical vocabulary thesaurus"
      },
      {
        "name": "ATC",
        "full_name": "Anatomical Therapeutic Chemical Classification",
        "url": "https://www.whocc.no/atc/",
        "description": "Drug classification system"
      },
      {
        "name": "ICD-10",
        "full_name": "International Classification of Diseases",
        "url": "https://icd.who.int/",
        "description": "Disease classification standard"
      },
      {
        "name": "SNOMED CT",
        "full_name": "Systematized Nomenclature of Medicine Clinical Terms",
        "url": "https://www.snomed.org/",
        "description": "Clinical terminology system"
      }
    ],
    "total_candidates": 77,
    "enrichment_statistics": {
      "total_candidates": 77,
      "enrichment_coverage": {
        "therapeutic_area": {
          "enriched_count": 70,
          "total_count": 77,
          "coverage_percentage": 90.9
        },
        "indication": {
          "enriched_count": 46,
          "total_count": 77,
          "coverage_percentage": 59.7
        },
        "compound_type": {
          "enriched_count": 53,
          "total_count": 77,
          "coverage_percentage": 68.8
        },
        "development_phase": {
          "enriched_count": 77,
          "total_count": 77,
          "coverage_percentage": 100.0
        },
        "mechanism_of_action": {
          "enriched_count": 11,
          "total_count": 77,
          "coverage_percentage": 14.3
        }
      },
      "ontology_usage": {
        "MONDO": 97,
        "ChEBI": 48,
        "EFO": 70,
        "NCIT": 130,
        "MeSH": 118,
        "ATC": 38,
        "ICD-10": 46,
        "SNOMED_CT": 46
      },
      "unique_terms": {
        "therapeutic_areas": 8,
        "indications": 28,
        "compound_types": 6,
        "development_phases": 4,
        "mechanisms": 8,
        "regulatory_designations": 1
      }
    }
  },
  "ontological_vocabularies": {
    "therapeutic_areas": {
      "Diabetes": {
        "efo_id": "EFO_0000400",
        "efo_label": "diabetes mellitus",
        "mesh_id": "D003920",
        "mesh_label": "Diabetes Mellitus",
        "mondo_id": "MONDO_0005015",
        "mondo_label": "diabetes mellitus"
      },
      "Obesity": {
        "efo_id": "EFO_0001073",
        "efo_label": "obesity",
        "mesh_id": "D009765",
        "mesh_label": "Obesity",
        "mondo_id": "MONDO_0011122",
        "mondo_label": "obesity disorder"
      },
      "Cardiovascular/Metabolic": {
        "efo_id": "EFO_0000319",
        "efo_label": "cardiovascular disease",
        "mesh_id": "D002318",
        "mesh_label": "Cardiovascular Diseases",
        "atc_class": "C",
        "atc_label": "Cardiovascular System"
      },
      "Rare Diseases": {
        "efo_id": "EFO_0000651",
        "efo_label": "rare disease",
        "mesh_id": "D035583",
        "mesh_label": "Rare Diseases",
        "mondo_id": "MONDO_0021136",
        "mondo_label": "rare genetic disease"
      },
      "Vaccines": {
        "efo_id": "EFO_0000876",
        "efo_label": "vaccine",
        "mesh_id": "D014612",
        "mesh_label": "Vaccines",
        "atc_class": "J07",
        "atc_label": "Vaccines"
      },
      "Immunology": {
        "efo_id": "EFO_0000540",
        "efo_label": "immune system disease",
        "mesh_id": "D007154",
        "mesh_label": "Immune System Diseases",
        "atc_class": "L",
        "atc_label": "Antineoplastic and Immunomodulating Agents"
      },
      "Oncology": {
        "efo_id": "EFO_0000616",
        "efo_label": "neoplasm",
        "mesh_id": "D009369",
        "mesh_label": "Neoplasms",
        "mondo_id": "MONDO_0004992",
        "mondo_label": "cancer",
        "atc_class": "L01",
        "atc_label": "Antineoplastic Agents"
      },
      "Neuroscience": {
        "efo_id": "EFO_0000618",
        "efo_label": "nervous system disease",
        "mesh_id": "D009422",
        "mesh_label": "Nervous System Diseases",
        "atc_class": "N",
        "atc_label": "Nervous System"
      }
    },
    "indications": {
      "Type 1 diabetes": {
        "mondo_id": "MONDO_0005147",
        "mondo_label": "type 1 diabetes mellitus",
        "mesh_id": "D003922",
        "mesh_label": "Diabetes Mellitus, Type 1",
        "icd10": "E10",
        "snomed_ct": "46635009"
      },
      "Obesity": {
        "mondo_id": "MONDO_0011122",
        "mondo_label": "obesity disorder",
        "mesh_id": "D009765",
        "mesh_label": "Obesity",
        "icd10": "E66",
        "snomed_ct": "414915002"
      },
      "Obesity, type 2 diabetes and other diseases": {
        "mondo_id": "MONDO_0005148",
        "mondo_label": "type 2 diabetes mellitus",
        "mesh_id": "D003924",
        "mesh_label": "Diabetes Mellitus, Type 2",
        "icd10": "E11",
        "snomed_ct": "44054006"
      },
      "Heart failure": {
        "mondo_id": "MONDO_0005252",
        "mondo_label": "heart failure",
        "mesh_id": "D006333",
        "mesh_label": "Heart Failure",
        "icd10": "I50",
        "snomed_ct": "84114007"
      },
      "Parkinson's Disease": {
        "mondo_id": "MONDO_0005180",
        "mondo_label": "Parkinson disease",
        "mesh_id": "D010300",
        "mesh_label": "Parkinson Disease",
        "icd10": "G20",
        "snomed_ct": "49049000"
      },
      "Haemophilia": {
        "mondo_id": "MONDO_0001475",
        "mondo_label": "hemophilia",
        "mesh_id": "D006467",
        "mesh_label": "Hemophilia A",
        "icd10": "D66",
        "snomed_ct": "90935002"
      },
      "Diabetes": {
        "mondo_id": "MONDO_0005147",
        "mondo_label": "type 1 diabetes mellitus",
        "mesh_id": "D003922",
        "mesh_label": "Diabetes Mellitus, Type 1",
        "icd10": "E10",
        "snomed_ct": "46635009"
      },
      "Type 2 diabetes": {
        "mondo_id": "MONDO_0005148",
        "mondo_label": "type 2 diabetes mellitus",
        "mesh_id": "D003924",
        "mesh_label": "Diabetes Mellitus, Type 2",
        "icd10": "E11",
        "snomed_ct": "44054006"
      },
      "Heart failure with reduced ejection fraction (HFrEF)": {
        "mondo_id": "MONDO_0005252",
        "mondo_label": "heart failure",
        "mesh_id": "D006333",
        "mesh_label": "Heart Failure",
        "icd10": "I50",
        "snomed_ct": "84114007"
      },
      "Sickle cell disease": {
        "mondo_id": "MONDO_0011382",
        "mondo_label": "sickle cell disease",
        "mesh_id": "D000755",
        "mesh_label": "Anemia, Sickle Cell",
        "icd10": "D57",
        "snomed_ct": "417357006"
      },
      "Thalassemia": {
        "mondo_id": "MONDO_0019402",
        "mondo_label": "thalassemia",
        "mesh_id": "D013789",
        "mesh_label": "Thalassemia",
        "icd10": "D56",
        "snomed_ct": "40108008"
      },
      "Heart failure with preserved ejection fraction (HFpEF)": {
        "mondo_id": "MONDO_0005252",
        "mondo_label": "heart failure",
        "mesh_id": "D006333",
        "mesh_label": "Heart Failure",
        "icd10": "I50",
        "snomed_ct": "84114007"
      },
      "Alzheimer's disease": {
        "mondo_id": "MONDO_0004975",
        "mondo_label": "Alzheimer disease",
        "mesh_id": "D000544",
        "mesh_label": "Alzheimer Disease",
        "icd10": "G30",
        "snomed_ct": "26929004"
      },
      "Haemophilia A with or without inhibitors": {
        "mondo_id": "MONDO_0001475",
        "mondo_label": "hemophilia",
        "mesh_id": "D006467",
        "mesh_label": "Hemophilia A",
        "icd10": "D66",
        "snomed_ct": "90935002"
      },
      "Sickle Cell Disease": {
        "mondo_id": "MONDO_0011382",
        "mondo_label": "sickle cell disease",
        "mesh_id": "D000755",
        "mesh_label": "Anemia, Sickle Cell",
        "icd10": "D57",
        "snomed_ct": "417357006"
      },
      "Haemophilia A and B with inhibitors": {
        "mondo_id": "MONDO_0001475",
        "mondo_label": "hemophilia",
        "mesh_id": "D006467",
        "mesh_label": "Hemophilia A",
        "icd10": "D66",
        "snomed_ct": "90935002"
      },
      "Rheumatoid Arthritis (Biologic)": {
        "mondo_id": "MONDO_0008383",
        "mondo_label": "rheumatoid arthritis",
        "mesh_id": "D001172",
        "mesh_label": "Arthritis, Rheumatoid",
        "icd10": "M06",
        "snomed_ct": "69896004"
      },
      "Ulcerative Colitis": {
        "mondo_id": "MONDO_0005101",
        "mondo_label": "ulcerative colitis",
        "mesh_id": "D003093",
        "mesh_label": "Colitis, Ulcerative",
        "icd10": "K51",
        "snomed_ct": "64766004"
      },
      "Inflammatory Bowel Disease": {
        "mondo_id": "MONDO_0005265",
        "mondo_label": "inflammatory bowel disease",
        "mesh_id": "D015212",
        "mesh_label": "Inflammatory Bowel Diseases",
        "icd10": "K50-K52",
        "snomed_ct": "24526004"
      },
      "Glioblastoma": {
        "mondo_id": "MONDO_0018177",
        "mondo_label": "glioblastoma",
        "mesh_id": "D005909",
        "mesh_label": "Glioblastoma",
        "icd10": "C71",
        "snomed_ct": "393563007"
      },
      "Breast cancer": {
        "mondo_id": "MONDO_0007254",
        "mondo_label": "breast cancer",
        "mesh_id": "D001943",
        "mesh_label": "Breast Neoplasms",
        "icd10": "C50",
        "snomed_ct": "254837009"
      },
      "Glioblastoma multiforme": {
        "mondo_id": "MONDO_0018177",
        "mondo_label": "glioblastoma",
        "mesh_id": "D005909",
        "mesh_label": "Glioblastoma",
        "icd10": "C71",
        "snomed_ct": "393563007"
      },
      "Metastatic hormone sensitive prostate cancer (mHSPC)": {
        "mondo_id": "MONDO_0008315",
        "mondo_label": "prostate cancer",
        "mesh_id": "D011471",
        "mesh_label": "Prostatic Neoplasms",
        "icd10": "C61",
        "snomed_ct": "399068003"
      },
      "Oligometastatic prostate cancer": {
        "mondo_id": "MONDO_0008315",
        "mondo_label": "prostate cancer",
        "mesh_id": "D011471",
        "mesh_label": "Prostatic Neoplasms",
        "icd10": "C61",
        "snomed_ct": "399068003"
      },
      "Metastatic neuroendocrine prostate cancer": {
        "mondo_id": "MONDO_0008315",
        "mondo_label": "prostate cancer",
        "mesh_id": "D011471",
        "mesh_label": "Prostatic Neoplasms",
        "icd10": "C61",
        "snomed_ct": "399068003"
      },
      "Prostate cancer": {
        "mondo_id": "MONDO_0008315",
        "mondo_label": "prostate cancer",
        "mesh_id": "D011471",
        "mesh_label": "Prostatic Neoplasms",
        "icd10": "C61",
        "snomed_ct": "399068003"
      },
      "Metastatic castration-resistant prostate cancer": {
        "mondo_id": "MONDO_0008315",
        "mondo_label": "prostate cancer",
        "mesh_id": "D011471",
        "mesh_label": "Prostatic Neoplasms",
        "icd10": "C61",
        "snomed_ct": "399068003"
      },
      "Multiple sclerosis, pediatrics": {
        "mondo_id": "MONDO_0005301",
        "mondo_label": "multiple sclerosis",
        "mesh_id": "D009103",
        "mesh_label": "Multiple Sclerosis",
        "icd10": "G35",
        "snomed_ct": "24700007"
      }
    },
    "compound_types": {
      "Biologic": {
        "chebi_id": "CHEBI_33695",
        "chebi_label": "biological macromolecule",
        "ncit_id": "C1909",
        "ncit_label": "Biological Products",
        "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
      },
      "Small Molecule": {
        "chebi_id": "CHEBI_25367",
        "chebi_label": "molecule",
        "ncit_id": "C1908",
        "ncit_label": "Chemical",
        "definition": "Low molecular weight compounds typically under 900 daltons"
      },
      "Cell Therapy": {
        "ncit_id": "C15262",
        "ncit_label": "Cell Therapy",
        "mesh_id": "D064987",
        "mesh_label": "Cell- and Tissue-Based Therapy",
        "definition": "Treatment using living cells to restore or establish normal function"
      },
      "RNA Therapy": {
        "chebi_id": "CHEBI_33697",
        "chebi_label": "ribonucleic acid",
        "ncit_id": "C13280",
        "ncit_label": "RNA",
        "definition": "Therapeutic use of RNA molecules including siRNA, mRNA, and antisense oligonucleotides"
      },
      "Vaccine": {
        "chebi_id": "CHEBI_59132",
        "chebi_label": "vaccine",
        "ncit_id": "C906",
        "ncit_label": "Vaccine",
        "definition": "Biological preparation that provides immunity to a particular infectious disease"
      },
      "Radioligand": {
        "ncit_id": "C17262",
        "ncit_label": "Radioligand",
        "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
      }
    },
    "development_phases": {
      "Phase 1": {
        "ncit_id": "C15600",
        "ncit_label": "Phase I Trial",
        "definition": "Initial studies to determine safety and dosage range"
      },
      "Phase 2": {
        "ncit_id": "C15601",
        "ncit_label": "Phase II Trial",
        "definition": "Studies to assess effectiveness while monitoring safety"
      },
      "Phase 3": {
        "ncit_id": "C15602",
        "ncit_label": "Phase III Trial",
        "definition": "Large-scale studies comparing new treatment to standard treatment"
      },
      "Registration/Filed": {
        "ncit_id": "C25646",
        "ncit_label": "Regulatory Submission",
        "definition": "Submission of data to regulatory authorities for approval"
      }
    },
    "mechanisms": {
      "A novel insulin analogue ideal for use in a closed loop pump device as delivery.": {
        "chebi_id": "CHEBI_145810",
        "chebi_label": "insulin",
        "go_id": "GO_0005179",
        "go_label": "hormone activity"
      },
      "A glucose-sensitive insulin analogue intended for once-daily treatment.": {
        "chebi_id": "CHEBI_145810",
        "chebi_label": "insulin",
        "go_id": "GO_0005179",
        "go_label": "hormone activity"
      },
      "A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function.": {
        "chebi_id": "CHEBI_145810",
        "chebi_label": "insulin",
        "go_id": "GO_0005179",
        "go_label": "hormone activity"
      },
      "A monoclonal antibody in development for cardiovascular disease": {
        "chebi_id": "CHEBI_59132",
        "chebi_label": "monoclonal antibody",
        "go_id": "GO_0003823",
        "go_label": "antigen binding"
      },
      "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity": {
        "chebi_id": "CHEBI_59132",
        "chebi_label": "monoclonal antibody",
        "go_id": "GO_0003823",
        "go_label": "antigen binding"
      },
      "A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment": {
        "chebi_id": "CHEBI_145810",
        "chebi_label": "insulin",
        "go_id": "GO_0005179",
        "go_label": "hormone activity"
      },
      "A long-acting basal insulin analogue intended for once weekly dosing": {
        "chebi_id": "CHEBI_145810",
        "chebi_label": "insulin",
        "go_id": "GO_0005179",
        "go_label": "hormone activity"
      },
      "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)": {
        "chebi_id": "CHEBI_59132",
        "chebi_label": "monoclonal antibody",
        "go_id": "GO_0003823",
        "go_label": "antigen binding"
      }
    },
    "regulatory_designations": {
      "Fast Track": {
        "ncit_id": "C48660",
        "ncit_label": "Fast Track Designation",
        "definition": "FDA designation for drugs addressing unmet medical needs"
      }
    }
  },
  "enriched_pipeline": [
    {
      "candidate_id": "NVO_001",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Pumpsulin",
      "compound_code": "NN1471/Insulin 119",
      "brand_name": null,
      "indication": "Type 1 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel insulin analogue ideal for use in a closed loop pump device as delivery.",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Pumpsulin",
        "code": "NN1471/Insulin 119",
        "indication": "Type 1 diabetes",
        "therapy_area": "Diabetes",
        "description": "A novel insulin analogue ideal for use in a closed loop pump device as delivery."
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005147",
          "mondo_label": "type 1 diabetes mellitus",
          "mesh_id": "D003922",
          "mesh_label": "Diabetes Mellitus, Type 1",
          "icd10": "E10",
          "snomed_ct": "46635009"
        },
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_145810",
          "chebi_label": "insulin",
          "go_id": "GO_0005179",
          "go_label": "hormone activity"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_002",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Glucose sensitive insulin",
      "compound_code": "NN1845/GSI/Insulin 845",
      "brand_name": null,
      "indication": "Type 1 and 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A glucose-sensitive insulin analogue intended for once-daily treatment.",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Glucose sensitive insulin",
        "code": "NN1845/GSI/Insulin 845",
        "indication": "Type 1 and 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A glucose-sensitive insulin analogue intended for once-daily treatment."
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_145810",
          "chebi_label": "insulin",
          "go_id": "GO_0005179",
          "go_label": "hormone activity"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_003",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "DNA immunotherapy",
      "compound_code": "NN9041",
      "brand_name": null,
      "indication": "Type 1 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function.",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "DNA immunotherapy",
        "code": "NN9041",
        "indication": "Type 1 diabetes",
        "therapy_area": "Diabetes",
        "description": "A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function."
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005147",
          "mondo_label": "type 1 diabetes mellitus",
          "mesh_id": "D003922",
          "mesh_label": "Diabetes Mellitus, Type 1",
          "icd10": "E10",
          "snomed_ct": "46635009"
        },
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_145810",
          "chebi_label": "insulin",
          "go_id": "GO_0005179",
          "go_label": "hormone activity"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_004",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Amylin 355",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once-weekly subcutaneous amylin analogue for the treatment of obesity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Amylin 355",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous amylin analogue for the treatment of obesity"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_005",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Amycretin",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Amycretin",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_006",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Subcutaneous Amycretin",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Subcutaneous Amycretin",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_007",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "INV-347",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "Next generation oral small molecule CB1 receptor blocker",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "INV-347",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "Next generation oral small molecule CB1 receptor blocker"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_008",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "UBT251 (GGG tri-agonist)",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity, type 2 diabetes and other diseases",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A triple agonist of the receptors for GLP-1, GIP, and glucagon",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "UBT251 (GGG tri-agonist)",
        "indication": "Obesity, type 2 diabetes and other diseases",
        "therapy_area": "Obesity",
        "description": "A triple agonist of the receptors for GLP-1, GIP, and glucagon"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0005148",
          "mondo_label": "type 2 diabetes mellitus",
          "mesh_id": "D003924",
          "mesh_label": "Diabetes Mellitus, Type 2",
          "icd10": "E11",
          "snomed_ct": "44054006"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_009",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Amylin 1213",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once-weekly subcutaneous amylin analogue for the treatment of obesity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Amylin 1213",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous amylin analogue for the treatment of obesity"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_010",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Tri-agonist",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once-weekly subcutaneous tri-agonist for the treatment of obesity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Tri-agonist",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous tri-agonist for the treatment of obesity"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_011",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Anti ANGPTL3",
      "compound_code": "",
      "brand_name": null,
      "indication": "Cardiovascular disease",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A monoclonal antibody in development for cardiovascular disease",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Anti ANGPTL3",
        "indication": "Cardiovascular disease",
        "therapy_area": "Cardiovascular Disease",
        "description": "A monoclonal antibody in development for cardiovascular disease"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_59132",
          "chebi_label": "monoclonal antibody",
          "go_id": "GO_0003823",
          "go_label": "antigen binding"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_012",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "CNP",
      "compound_code": "",
      "brand_name": null,
      "indication": "Heart failure",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "A C-type natriuretic peptide (CNP) analogue in development for heart failure",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CNP",
        "indication": "Heart failure",
        "therapy_area": "Cardiovascular Disease",
        "description": "A C-type natriuretic peptide (CNP) analogue in development for heart failure"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {
          "mondo_id": "MONDO_0005252",
          "mondo_label": "heart failure",
          "mesh_id": "D006333",
          "mesh_label": "Heart Failure",
          "icd10": "I50",
          "snomed_ct": "84114007"
        },
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_013",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "NLRP3 inhibitor",
      "compound_code": "",
      "brand_name": null,
      "indication": "Cardiovascular disease",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "An oral treatment in a broad range of liver, kidney and cardiometabolic diseases",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "NLRP3 inhibitor",
        "indication": "Cardiovascular disease",
        "therapy_area": "Cardiovascular Disease",
        "description": "An oral treatment in a broad range of liver, kidney and cardiometabolic diseases"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_014",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Cell Therapy in heart failure",
      "compound_code": "",
      "brand_name": null,
      "indication": "Heart failure",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Cell Therapy",
      "mechanism_of_action": "A cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Cell Therapy in heart failure",
        "indication": "Heart failure",
        "therapy_area": "Cardiovascular Disease",
        "description": "A cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC)"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {
          "mondo_id": "MONDO_0005252",
          "mondo_label": "heart failure",
          "mesh_id": "D006333",
          "mesh_label": "Heart Failure",
          "icd10": "I50",
          "snomed_ct": "84114007"
        },
        "compound_type": {
          "ncit_id": "C15262",
          "ncit_label": "Cell Therapy",
          "mesh_id": "D064987",
          "mesh_label": "Cell- and Tissue-Based Therapy",
          "definition": "Treatment using living cells to restore or establish normal function"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_015",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "MARC1",
      "compound_code": "",
      "brand_name": null,
      "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 1",
      "compound_type": "RNA Therapy",
      "mechanism_of_action": "An siRNA targeting MARC1 for subcutaneous treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "MARC1",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "An siRNA targeting MARC1 for subcutaneous treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {},
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33697",
          "chebi_label": "ribonucleic acid",
          "ncit_id": "C13280",
          "ncit_label": "RNA",
          "definition": "Therapeutic use of RNA molecules including siRNA, mRNA, and antisense oligonucleotides"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_016",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "LXRα",
      "compound_code": "",
      "brand_name": null,
      "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 1",
      "compound_type": "RNA Therapy",
      "mechanism_of_action": "An siRNA targeting LXRα for subcutaneous treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "LXRα",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "An siRNA targeting LXRα for subcutaneous treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {},
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33697",
          "chebi_label": "ribonucleic acid",
          "ncit_id": "C13280",
          "ncit_label": "RNA",
          "definition": "Therapeutic use of RNA molecules including siRNA, mRNA, and antisense oligonucleotides"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_017",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Cell therapy in Parkinson's disease",
      "compound_code": "",
      "brand_name": null,
      "indication": "Parkinson's Disease",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 1",
      "compound_type": "Cell Therapy",
      "mechanism_of_action": "A cell therapy using stem cell-derived nerve cells",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Cell therapy in Parkinson's disease",
        "indication": "Parkinson's Disease",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A cell therapy using stem cell-derived nerve cells"
      },
      "ontological_annotations": {
        "therapeutic_area": {},
        "indication": {
          "mondo_id": "MONDO_0005180",
          "mondo_label": "Parkinson disease",
          "mesh_id": "D010300",
          "mesh_label": "Parkinson Disease",
          "icd10": "G20",
          "snomed_ct": "49049000"
        },
        "compound_type": {
          "ncit_id": "C15262",
          "ncit_label": "Cell Therapy",
          "mesh_id": "D064987",
          "mesh_label": "Cell- and Tissue-Based Therapy",
          "definition": "Treatment using living cells to restore or establish normal function"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_018",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Inno8",
      "compound_code": "",
      "brand_name": null,
      "indication": "Haemophilia",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": "An oral, once-daily antibody fragment for the treatment of haemophilia",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Inno8",
        "indication": "Haemophilia",
        "therapy_area": "Rare Blood Disorders",
        "description": "An oral, once-daily antibody fragment for the treatment of haemophilia"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000651",
          "efo_label": "rare disease",
          "mesh_id": "D035583",
          "mesh_label": "Rare Diseases",
          "mondo_id": "MONDO_0021136",
          "mondo_label": "rare genetic disease"
        },
        "indication": {
          "mondo_id": "MONDO_0001475",
          "mondo_label": "hemophilia",
          "mesh_id": "D006467",
          "mesh_label": "Hemophilia A",
          "icd10": "D66",
          "snomed_ct": "90935002"
        },
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_019",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "TMPRSS6",
      "compound_code": "",
      "brand_name": null,
      "indication": "Hereditary Haemochromatosis",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 1",
      "compound_type": "Unknown",
      "mechanism_of_action": "An RNAi in development for the rare blood disease Hereditary Haemochromatosis",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "TMPRSS6",
        "indication": "Hereditary Haemochromatosis",
        "therapy_area": "Rare Blood Disorders",
        "description": "An RNAi in development for the rare blood disease Hereditary Haemochromatosis"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000651",
          "efo_label": "rare disease",
          "mesh_id": "D035583",
          "mesh_label": "Rare Diseases",
          "mondo_id": "MONDO_0021136",
          "mondo_label": "rare genetic disease"
        },
        "indication": {},
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_020",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Subcutaneous Amycretin",
      "compound_code": "",
      "brand_name": null,
      "indication": "Diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Subcutaneous Amycretin",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005147",
          "mondo_label": "type 1 diabetes mellitus",
          "mesh_id": "D003922",
          "mesh_label": "Diabetes Mellitus, Type 1",
          "icd10": "E10",
          "snomed_ct": "46635009"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_021",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Monlunabant in DKD",
      "compound_code": "INV-202",
      "brand_name": null,
      "indication": "Diabetic Kidney Disease (DKD)",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "An oral small molecule CB1 receptor blocker",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Monlunabant in DKD",
        "code": "INV-202",
        "indication": "Diabetic Kidney Disease (DKD)",
        "therapy_area": "Diabetes",
        "description": "An oral small molecule CB1 receptor blocker"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_022",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Once weekly GLP-1/GIP",
      "compound_code": "",
      "brand_name": null,
      "indication": "Diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Once weekly GLP-1/GIP",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005147",
          "mondo_label": "type 1 diabetes mellitus",
          "mesh_id": "D003922",
          "mesh_label": "Diabetes Mellitus, Type 1",
          "icd10": "E10",
          "snomed_ct": "46635009"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_023",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Amycretin",
      "compound_code": "",
      "brand_name": null,
      "indication": "Diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Amycretin",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005147",
          "mondo_label": "type 1 diabetes mellitus",
          "mesh_id": "D003922",
          "mesh_label": "Diabetes Mellitus, Type 1",
          "icd10": "E10",
          "snomed_ct": "46635009"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_024",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "FUSE",
      "compound_code": "NN9506",
      "brand_name": null,
      "indication": "Type 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "FUSE",
        "code": "NN9506",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005148",
          "mondo_label": "type 2 diabetes mellitus",
          "mesh_id": "D003924",
          "mesh_label": "Diabetes Mellitus, Type 2",
          "icd10": "E11",
          "snomed_ct": "44054006"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_025",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "FUSE",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "FUSE",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_026",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Once weekly GLP-1/GIP",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Once weekly GLP-1/GIP",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_027",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Monlunabant",
      "compound_code": "INV-202",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "An oral small molecule CB1 receptor blocker",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Monlunabant",
        "code": "INV-202",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "An oral small molecule CB1 receptor blocker"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_028",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "CDR132L",
      "compound_code": "",
      "brand_name": null,
      "indication": "Heart failure with reduced ejection fraction (HFrEF)",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "An antisense oligonucleotide (ASO) targeting the microRNA molecule miR-132",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CDR132L",
        "indication": "Heart failure with reduced ejection fraction (HFrEF)",
        "therapy_area": "Cardiovascular Disease",
        "description": "An antisense oligonucleotide (ASO) targeting the microRNA molecule miR-132"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {
          "mondo_id": "MONDO_0005252",
          "mondo_label": "heart failure",
          "mesh_id": "D006333",
          "mesh_label": "Heart Failure",
          "icd10": "I50",
          "snomed_ct": "84114007"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_029",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "NDec",
      "compound_code": "Eclipse/EPI01/NN7533",
      "brand_name": null,
      "indication": "Sickle cell disease",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "An oral combination of decitabine and tetrahydrouridine",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "NDec",
        "code": "Eclipse/EPI01/NN7533",
        "indication": "Sickle cell disease",
        "therapy_area": "Rare Blood Disorders",
        "description": "An oral combination of decitabine and tetrahydrouridine"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000651",
          "efo_label": "rare disease",
          "mesh_id": "D035583",
          "mesh_label": "Rare Diseases",
          "mondo_id": "MONDO_0021136",
          "mondo_label": "rare genetic disease"
        },
        "indication": {
          "mondo_id": "MONDO_0011382",
          "mondo_label": "sickle cell disease",
          "mesh_id": "D000755",
          "mesh_label": "Anemia, Sickle Cell",
          "icd10": "D57",
          "snomed_ct": "417357006"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_030",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Coramitug",
      "compound_code": "PRX004/NN6019",
      "brand_name": null,
      "indication": "ATTR Cardiomyopathy",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "An anti-amyloid immunotherapy treatment for ATTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Coramitug",
        "code": "PRX004/NN6019",
        "indication": "ATTR Cardiomyopathy",
        "therapy_area": "Cardiovascular Disease",
        "description": "An anti-amyloid immunotherapy treatment for ATTR"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {},
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_031",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Zalfermin",
      "compound_code": "NN9500",
      "brand_name": null,
      "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting FGF21 analogue for once-weekly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Zalfermin",
        "code": "NN9500",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A long-acting FGF21 analogue for once-weekly treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {},
        "indication": {},
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_032",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Etavopivat",
      "compound_code": "",
      "brand_name": null,
      "indication": "Thalassemia",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 2",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "A selective pyruvate kinase-R (PKR) activator intended for once daily oral treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Etavopivat",
        "indication": "Thalassemia",
        "therapy_area": "Rare Blood Disorders",
        "description": "A selective pyruvate kinase-R (PKR) activator intended for once daily oral treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000651",
          "efo_label": "rare disease",
          "mesh_id": "D035583",
          "mesh_label": "Rare Diseases",
          "mondo_id": "MONDO_0021136",
          "mondo_label": "rare genetic disease"
        },
        "indication": {
          "mondo_id": "MONDO_0019402",
          "mondo_label": "thalassemia",
          "mesh_id": "D013789",
          "mesh_label": "Thalassemia",
          "icd10": "D56",
          "snomed_ct": "40108008"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_033",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Semaglutide 25 mg and 50 mg",
      "compound_code": "NN9924",
      "brand_name": null,
      "indication": "Type 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 3",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "Oral GLP-1 25 and 50 mg, intended for once-daily treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Semaglutide 25 mg and 50 mg",
        "code": "NN9924",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "Oral GLP-1 25 and 50 mg, intended for once-daily treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005148",
          "mondo_label": "type 2 diabetes mellitus",
          "mesh_id": "D003924",
          "mesh_label": "Diabetes Mellitus, Type 2",
          "icd10": "E11",
          "snomed_ct": "44054006"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_034",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "CagriSema in T2D",
      "compound_code": "NN9388",
      "brand_name": null,
      "indication": "Type 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "A combination of amylin analogue and GLP-1 analogue semaglutide intended for once-weekly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CagriSema in T2D",
        "code": "NN9388",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A combination of amylin analogue and GLP-1 analogue semaglutide intended for once-weekly treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005148",
          "mondo_label": "type 2 diabetes mellitus",
          "mesh_id": "D003924",
          "mesh_label": "Diabetes Mellitus, Type 2",
          "icd10": "E11",
          "snomed_ct": "44054006"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_035",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "CagriSema",
      "compound_code": "NN9898",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "A combination of amylin analogue cagrilintide and GLP-1 analogue semaglutide intended for once-weekly subcutaneous treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CagriSema",
        "code": "NN9898",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A combination of amylin analogue cagrilintide and GLP-1 analogue semaglutide intended for once-weekly subcutaneous treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_036",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Semaglutide 7.2 mg",
      "compound_code": "",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Semaglutide 7.2 mg",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_037",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Ziltivekimab ASCVD",
      "compound_code": "NN6018",
      "brand_name": null,
      "indication": "Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD) and inflammation",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Ziltivekimab ASCVD",
        "code": "NN6018",
        "indication": "Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD) and inflammation",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_59132",
          "chebi_label": "monoclonal antibody",
          "go_id": "GO_0003823",
          "go_label": "antigen binding"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_038",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Ziltivekimabin HFpEF",
      "compound_code": "",
      "brand_name": null,
      "indication": "Heart failure with preserved ejection fraction (HFpEF)",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Ziltivekimabin HFpEF",
        "indication": "Heart failure with preserved ejection fraction (HFpEF)",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {
          "mondo_id": "MONDO_0005252",
          "mondo_label": "heart failure",
          "mesh_id": "D006333",
          "mesh_label": "Heart Failure",
          "icd10": "I50",
          "snomed_ct": "84114007"
        },
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_59132",
          "chebi_label": "monoclonal antibody",
          "go_id": "GO_0003823",
          "go_label": "antigen binding"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_039",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Ziltivekimab AMI",
      "compound_code": "",
      "brand_name": null,
      "indication": "Acute Myocardial infarction (AMI)",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Ziltivekimab AMI",
        "indication": "Acute Myocardial infarction (AMI)",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_59132",
          "chebi_label": "monoclonal antibody",
          "go_id": "GO_0003823",
          "go_label": "antigen binding"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_040",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Semaglutide Alzheimer's",
      "compound_code": "",
      "brand_name": null,
      "indication": "Alzheimer's disease",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 3",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "Oral semaglutide 14 mg once-daily for the treatment of early Alzheimer's disease",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Semaglutide Alzheimer's",
        "indication": "Alzheimer's disease",
        "therapy_area": "Emerging Therapy Areas",
        "description": "Oral semaglutide 14 mg once-daily for the treatment of early Alzheimer's disease"
      },
      "ontological_annotations": {
        "therapeutic_area": {},
        "indication": {
          "mondo_id": "MONDO_0004975",
          "mondo_label": "Alzheimer disease",
          "mesh_id": "D000544",
          "mesh_label": "Alzheimer Disease",
          "icd10": "G30",
          "snomed_ct": "26929004"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_041",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Mim8",
      "compound_code": "NN7769",
      "brand_name": null,
      "indication": "Haemophilia A with or without inhibitors",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Mim8",
        "code": "NN7769",
        "indication": "Haemophilia A with or without inhibitors",
        "therapy_area": "Rare Blood Disorders",
        "description": "A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000651",
          "efo_label": "rare disease",
          "mesh_id": "D035583",
          "mesh_label": "Rare Diseases",
          "mondo_id": "MONDO_0021136",
          "mondo_label": "rare genetic disease"
        },
        "indication": {
          "mondo_id": "MONDO_0001475",
          "mondo_label": "hemophilia",
          "mesh_id": "D006467",
          "mesh_label": "Hemophilia A",
          "icd10": "D66",
          "snomed_ct": "90935002"
        },
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_042",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Etavopivat (Sickle Cell Disease)",
      "compound_code": "",
      "brand_name": null,
      "indication": "Sickle Cell Disease",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Phase 3",
      "compound_type": "Small Molecule",
      "mechanism_of_action": "Oral, small molecule activator of erythrocyte pyruvate kinase (PKR)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Etavopivat (Sickle Cell Disease)",
        "indication": "Sickle Cell Disease",
        "therapy_area": "Rare Blood Disorders",
        "description": "Oral, small molecule activator of erythrocyte pyruvate kinase (PKR)"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000651",
          "efo_label": "rare disease",
          "mesh_id": "D035583",
          "mesh_label": "Rare Diseases",
          "mondo_id": "MONDO_0021136",
          "mondo_label": "rare genetic disease"
        },
        "indication": {
          "mondo_id": "MONDO_0011382",
          "mondo_label": "sickle cell disease",
          "mesh_id": "D000755",
          "mesh_label": "Anemia, Sickle Cell",
          "icd10": "D57",
          "snomed_ct": "417357006"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_043",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Icosema",
      "compound_code": "NN1535/LAIsema",
      "brand_name": null,
      "indication": "Type 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Registration/Filed",
      "compound_type": "Biologic",
      "mechanism_of_action": "A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Icosema",
        "code": "NN1535/LAIsema",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {
          "mondo_id": "MONDO_0005148",
          "mondo_label": "type 2 diabetes mellitus",
          "mesh_id": "D003924",
          "mesh_label": "Diabetes Mellitus, Type 2",
          "icd10": "E11",
          "snomed_ct": "44054006"
        },
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C25646",
          "ncit_label": "Regulatory Submission",
          "definition": "Submission of data to regulatory authorities for approval"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_145810",
          "chebi_label": "insulin",
          "go_id": "GO_0005179",
          "go_label": "hormone activity"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_044",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Insulin icodec",
      "compound_code": "NN1436/LAI287",
      "brand_name": null,
      "indication": "Type 1 and 2 diabetes",
      "therapeutic_area": "Diabetes",
      "development_phase": "Registration/Filed",
      "compound_type": "Biologic",
      "mechanism_of_action": "A long-acting basal insulin analogue intended for once weekly dosing",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Insulin icodec",
        "code": "NN1436/LAI287",
        "indication": "Type 1 and 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting basal insulin analogue intended for once weekly dosing"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000400",
          "efo_label": "diabetes mellitus",
          "mesh_id": "D003920",
          "mesh_label": "Diabetes Mellitus",
          "mondo_id": "MONDO_0005015",
          "mondo_label": "diabetes mellitus"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C25646",
          "ncit_label": "Regulatory Submission",
          "definition": "Submission of data to regulatory authorities for approval"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_145810",
          "chebi_label": "insulin",
          "go_id": "GO_0005179",
          "go_label": "hormone activity"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_045",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Oral Sema Obesity",
      "compound_code": "NN9932",
      "brand_name": null,
      "indication": "Obesity",
      "therapeutic_area": "Obesity",
      "development_phase": "Registration/Filed",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long acting GLP-1 analogue intended for once-daily treatment",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Oral Sema Obesity",
        "code": "NN9932",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long acting GLP-1 analogue intended for once-daily treatment"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0001073",
          "efo_label": "obesity",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder"
        },
        "indication": {
          "mondo_id": "MONDO_0011122",
          "mondo_label": "obesity disorder",
          "mesh_id": "D009765",
          "mesh_label": "Obesity",
          "icd10": "E66",
          "snomed_ct": "414915002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C25646",
          "ncit_label": "Regulatory Submission",
          "definition": "Submission of data to regulatory authorities for approval"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_046",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Semaglutide MASH",
      "compound_code": "",
      "brand_name": null,
      "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Registration/Filed",
      "compound_type": "Unknown",
      "mechanism_of_action": "A long-acting GLP-1 analogue for once-weekly treatment of MASH",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Semaglutide MASH",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A long-acting GLP-1 analogue for once-weekly treatment of MASH"
      },
      "ontological_annotations": {
        "therapeutic_area": {},
        "indication": {},
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C25646",
          "ncit_label": "Regulatory Submission",
          "definition": "Submission of data to regulatory authorities for approval"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVO_047",
      "company": "Novo Nordisk",
      "company_code": "NVO",
      "compound_name": "Concizumab",
      "compound_code": "",
      "brand_name": null,
      "indication": "Haemophilia A and B with inhibitors",
      "therapeutic_area": "Rare Diseases",
      "development_phase": "Registration/Filed",
      "compound_type": "Unknown",
      "mechanism_of_action": "Treatment for haemophilia A and B with inhibitors",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Concizumab",
        "indication": "Haemophilia A and B with inhibitors",
        "therapy_area": "Rare Blood Disorders",
        "description": "Treatment for haemophilia A and B with inhibitors"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000651",
          "efo_label": "rare disease",
          "mesh_id": "D035583",
          "mesh_label": "Rare Diseases",
          "mondo_id": "MONDO_0021136",
          "mondo_label": "rare genetic disease"
        },
        "indication": {
          "mondo_id": "MONDO_0001475",
          "mondo_label": "hemophilia",
          "mesh_id": "D006467",
          "mesh_label": "Hemophilia A",
          "icd10": "D66",
          "snomed_ct": "90935002"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C25646",
          "ncit_label": "Regulatory Submission",
          "definition": "Submission of data to regulatory authorities for approval"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_001",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "ABRYSVO",
      "compound_code": null,
      "brand_name": null,
      "indication": "Respiratory Syncytial Virus Infection (pediatric)",
      "therapeutic_area": "Vaccines",
      "development_phase": "Phase 1",
      "compound_type": "Vaccine",
      "mechanism_of_action": null,
      "submission_type": "Product Enhancement",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "ABRYSVO",
        "indication": "Respiratory Syncytial Virus Infection (pediatric)",
        "area_of_focus": "Vaccines",
        "submission_type": "Product Enhancement",
        "compound_type": "Vaccine",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000876",
          "efo_label": "vaccine",
          "mesh_id": "D014612",
          "mesh_label": "Vaccines",
          "atc_class": "J07",
          "atc_label": "Vaccines"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_59132",
          "chebi_label": "vaccine",
          "ncit_id": "C906",
          "ncit_label": "Vaccine",
          "definition": "Biological preparation that provides immunity to a particular infectious disease"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_002",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "CTB+AVP (PF-07612577)",
      "compound_code": "PF-07612577",
      "brand_name": null,
      "indication": "Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis (FAST TRACK - U.S.)",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [
        "Fast Track"
      ],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "CTB+AVP (PF-07612577)",
        "indication": "Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis (FAST TRACK - U.S.)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000540",
          "efo_label": "immune system disease",
          "mesh_id": "D007154",
          "mesh_label": "Immune System Diseases",
          "atc_class": "L",
          "atc_label": "Antineoplastic and Immunomodulating Agents"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": [
          {
            "designation": "Fast Track",
            "ontology": {
              "ncit_id": "C48660",
              "ncit_label": "Fast Track Designation",
              "definition": "FDA designation for drugs addressing unmet medical needs"
            }
          }
        ]
      }
    },
    {
      "candidate_id": "PFE_003",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "Dekavil",
      "compound_code": null,
      "brand_name": null,
      "indication": "Rheumatoid Arthritis (Biologic)",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "Dekavil",
        "indication": "Rheumatoid Arthritis (Biologic)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000540",
          "efo_label": "immune system disease",
          "mesh_id": "D007154",
          "mesh_label": "Immune System Diseases",
          "atc_class": "L",
          "atc_label": "Antineoplastic and Immunomodulating Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0008383",
          "mondo_label": "rheumatoid arthritis",
          "mesh_id": "D001172",
          "mesh_label": "Arthritis, Rheumatoid",
          "icd10": "M06",
          "snomed_ct": "69896004"
        },
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_004",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "felmetatug vedotin (PF-08046048) (B7H4V)",
      "compound_code": "PF-08046048",
      "brand_name": null,
      "indication": "Advanced Solid Tumors (Biologic)",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "felmetatug vedotin (PF-08046048) (B7H4V)",
        "indication": "Advanced Solid Tumors (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_005",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PADCEV (enfortumab vedotin)",
      "compound_code": null,
      "brand_name": null,
      "indication": "BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "Product Enhancement",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PADCEV (enfortumab vedotin)",
        "indication": "BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "Product Enhancement",
        "compound_type": "Biologic",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_006",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-06414300",
      "compound_code": "PF-06414300",
      "brand_name": null,
      "indication": "Ulcerative Colitis",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-06414300",
        "indication": "Ulcerative Colitis",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000540",
          "efo_label": "immune system disease",
          "mesh_id": "D007154",
          "mesh_label": "Immune System Diseases",
          "atc_class": "L",
          "atc_label": "Antineoplastic and Immunomodulating Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0005101",
          "mondo_label": "ulcerative colitis",
          "mesh_id": "D003093",
          "mesh_label": "Colitis, Ulcerative",
          "icd10": "K51",
          "snomed_ct": "64766004"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_007",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-06835375",
      "compound_code": "PF-06835375",
      "brand_name": null,
      "indication": "Lupus (Biologic)",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "Product Enhancement",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-06835375",
        "indication": "Lupus (Biologic)",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "Product Enhancement",
        "compound_type": "Biologic",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000540",
          "efo_label": "immune system disease",
          "mesh_id": "D007154",
          "mesh_label": "Immune System Diseases",
          "atc_class": "L",
          "atc_label": "Antineoplastic and Immunomodulating Agents"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_008",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-06940434",
      "compound_code": "PF-06940434",
      "brand_name": null,
      "indication": "Advanced Solid Tumors (Biologic)",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Biologic",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-06940434",
        "indication": "Advanced Solid Tumors (Biologic)",
        "area_of_focus": "Oncology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Biologic",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_009",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-06954522",
      "compound_code": "PF-06954522",
      "brand_name": null,
      "indication": "Chronic Weight Management",
      "therapeutic_area": "Cardiovascular/Metabolic",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-06954522",
        "indication": "Chronic Weight Management",
        "area_of_focus": "Internal Medicine",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000319",
          "efo_label": "cardiovascular disease",
          "mesh_id": "D002318",
          "mesh_label": "Cardiovascular Diseases",
          "atc_class": "C",
          "atc_label": "Cardiovascular System"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "PFE_010",
      "company": "Pfizer",
      "company_code": "PFE",
      "compound_name": "PF-07054894",
      "compound_code": "PF-07054894",
      "brand_name": null,
      "indication": "Inflammatory Bowel Disease",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 1",
      "compound_type": "Small Molecule",
      "mechanism_of_action": null,
      "submission_type": "New Molecular Entity",
      "regulatory_designations": [],
      "filing_date": null,
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "name": "PF-07054894",
        "indication": "Inflammatory Bowel Disease",
        "area_of_focus": "Inflammation & Immunology",
        "submission_type": "New Molecular Entity",
        "compound_type": "Small Molecule",
        "status": "Current"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000540",
          "efo_label": "immune system disease",
          "mesh_id": "D007154",
          "mesh_label": "Immune System Diseases",
          "atc_class": "L",
          "atc_label": "Antineoplastic and Immunomodulating Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0005265",
          "mondo_label": "inflammatory bowel disease",
          "mesh_id": "D015212",
          "mesh_label": "Inflammatory Bowel Diseases",
          "icd10": "K50-K52",
          "snomed_ct": "24526004"
        },
        "compound_type": {
          "chebi_id": "CHEBI_25367",
          "chebi_label": "molecule",
          "ncit_id": "C1908",
          "ncit_label": "Chemical",
          "definition": "Low molecular weight compounds typically under 900 daltons"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_001",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Gastroenteropancreatic neuroendocrine tumors",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 3",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "Gastroenteropancreatic neuroendocrine tumors",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 3",
        "mechanism": "Radioligand therapy target SSTR"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_002",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "GEPNET, pediatrics",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "GEPNET, pediatrics",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "mechanism": "Radioligand therapy target SSTR"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_003",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Glioblastoma",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "Glioblastoma",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "mechanism": "Radioligand therapy target SSTR"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0018177",
          "mondo_label": "glioblastoma",
          "mesh_id": "D005909",
          "mesh_label": "Glioblastoma",
          "icd10": "C71",
          "snomed_ct": "393563007"
        },
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_004",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "1L ES-SCLC",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "1L ES-SCLC",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "mechanism": "Radioligand therapy target SSTR"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_005",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA601",
      "compound_code": "AAA601",
      "brand_name": "Lutathera®",
      "indication": "Gastroenteropancreatic neuroendocrine tumors (GEP-NET), 1st line in G2/3 tumors",
      "therapeutic_area": "Oncology",
      "development_phase": "Registration/Filed",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target SSTR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2024",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA601",
        "brand_name": "Lutathera®",
        "indication": "Gastroenteropancreatic neuroendocrine tumors (GEP-NET), 1st line in G2/3 tumors",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Registration",
        "filing_date": "2024",
        "mechanism": "Radioligand therapy target SSTR"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C25646",
          "ncit_label": "Regulatory Submission",
          "definition": "Submission of data to regulatory authorities for approval"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_006",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA603",
      "compound_code": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Breast cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target GRPR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "≥ 2028",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA603",
        "brand_name": "177Lu-NeoB",
        "indication": "Breast cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "filing_date": "≥ 2028",
        "mechanism": "Radioligand therapy target GRPR"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0007254",
          "mondo_label": "breast cancer",
          "mesh_id": "D001943",
          "mesh_label": "Breast Neoplasms",
          "icd10": "C50",
          "snomed_ct": "254837009"
        },
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_007",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA603",
      "compound_code": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Glioblastoma multiforme",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target GRPR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "≥ 2028",
      "lead_indication": true,
      "status": "Current",
      "source_data": {
        "compound": "AAA603",
        "brand_name": "177Lu-NeoB",
        "indication": "Glioblastoma multiforme",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "filing_date": "≥ 2028",
        "mechanism": "Radioligand therapy target GRPR",
        "lead_indication": true
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0018177",
          "mondo_label": "glioblastoma",
          "mesh_id": "D005909",
          "mesh_label": "Glioblastoma",
          "icd10": "C71",
          "snomed_ct": "393563007"
        },
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_008",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA603",
      "compound_code": "AAA603",
      "brand_name": "177Lu-NeoB",
      "indication": "Multiple solid tumors",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target GRPR",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "≥ 2028",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA603",
        "brand_name": "177Lu-NeoB",
        "indication": "Multiple solid tumors",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "filing_date": "≥ 2028",
        "mechanism": "Radioligand therapy target GRPR"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_009",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA614",
      "compound_code": "AAA614",
      "brand_name": "AAA614",
      "indication": "Solid tumors",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target FAP",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": true,
      "status": "Current",
      "source_data": {
        "compound": "AAA614",
        "brand_name": "AAA614",
        "indication": "Solid tumors",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 2",
        "mechanism": "Radioligand therapy target FAP",
        "lead_indication": true
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_010",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA617",
      "compound_code": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Metastatic hormone sensitive prostate cancer (mHSPC)",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 3",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2025",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA617",
        "brand_name": "Pluvicto®",
        "indication": "Metastatic hormone sensitive prostate cancer (mHSPC)",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 3",
        "filing_date": "2025",
        "mechanism": "Radioligand therapy target PSMA"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0008315",
          "mondo_label": "prostate cancer",
          "mesh_id": "D011471",
          "mesh_label": "Prostatic Neoplasms",
          "icd10": "C61",
          "snomed_ct": "399068003"
        },
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_011",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA617",
      "compound_code": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Oligometastatic prostate cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 3",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2027",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA617",
        "brand_name": "Pluvicto®",
        "indication": "Oligometastatic prostate cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 3",
        "filing_date": "2027",
        "mechanism": "Radioligand therapy target PSMA"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0008315",
          "mondo_label": "prostate cancer",
          "mesh_id": "D011471",
          "mesh_label": "Prostatic Neoplasms",
          "icd10": "C61",
          "snomed_ct": "399068003"
        },
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_012",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA617",
      "compound_code": "AAA617",
      "brand_name": "Pluvicto®",
      "indication": "Metastatic neuroendocrine prostate cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2025",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AAA617",
        "brand_name": "Pluvicto®",
        "indication": "Metastatic neuroendocrine prostate cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "filing_date": "2025",
        "mechanism": "Radioligand therapy target PSMA"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0008315",
          "mondo_label": "prostate cancer",
          "mesh_id": "D011471",
          "mesh_label": "Prostatic Neoplasms",
          "icd10": "C61",
          "snomed_ct": "399068003"
        },
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_013",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA802",
      "compound_code": "AAA802",
      "brand_name": "225Ac-PSMA-R2",
      "indication": "Prostate cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": true,
      "status": "Current",
      "source_data": {
        "compound": "AAA802",
        "brand_name": "225Ac-PSMA-R2",
        "indication": "Prostate cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "mechanism": "Radioligand therapy target PSMA",
        "lead_indication": true
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0008315",
          "mondo_label": "prostate cancer",
          "mesh_id": "D011471",
          "mesh_label": "Prostatic Neoplasms",
          "icd10": "C61",
          "snomed_ct": "399068003"
        },
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_014",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AAA817",
      "compound_code": "AAA817",
      "brand_name": "225Ac-PSMA-617",
      "indication": "Metastatic castration-resistant prostate cancer",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 1",
      "compound_type": "Radioligand",
      "mechanism_of_action": "Radioligand therapy target PSMA",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": true,
      "status": "Current",
      "source_data": {
        "compound": "AAA817",
        "brand_name": "225Ac-PSMA-617",
        "indication": "Metastatic castration-resistant prostate cancer",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 1",
        "mechanism": "Radioligand therapy target PSMA",
        "lead_indication": true
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {
          "mondo_id": "MONDO_0008315",
          "mondo_label": "prostate cancer",
          "mesh_id": "D011471",
          "mesh_label": "Prostatic Neoplasms",
          "icd10": "C61",
          "snomed_ct": "399068003"
        },
        "compound_type": {
          "ncit_id": "C17262",
          "ncit_label": "Radioligand",
          "definition": "Radioactive compound that binds to specific molecular targets for imaging or therapy"
        },
        "development_phase": {
          "ncit_id": "C15600",
          "ncit_label": "Phase I Trial",
          "definition": "Initial studies to determine safety and dosage range"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_015",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "ABL001",
      "compound_code": "ABL001",
      "brand_name": "Scemblix®",
      "indication": "Chronic myeloid leukemia, pediatrics",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 2",
      "compound_type": "Unknown",
      "mechanism_of_action": "BCR-ABL inhibitor",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "ABL001",
        "brand_name": "Scemblix®",
        "indication": "Chronic myeloid leukemia, pediatrics",
        "therapeutic_area": "Oncology: Hematology",
        "phase": "Phase 2",
        "mechanism": "BCR-ABL inhibitor"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15601",
          "ncit_label": "Phase II Trial",
          "definition": "Studies to assess effectiveness while monitoring safety"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_016",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AIN457",
      "compound_code": "AIN457",
      "brand_name": "Cosentyx®",
      "indication": "Giant cell arteritis (GCA)",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2025",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AIN457",
        "brand_name": "Cosentyx®",
        "indication": "Giant cell arteritis (GCA)",
        "therapeutic_area": "Immunology",
        "phase": "Phase 3",
        "filing_date": "2025",
        "mechanism": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)",
        "supplementary_indication": true
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000540",
          "efo_label": "immune system disease",
          "mesh_id": "D007154",
          "mesh_label": "Immune System Diseases",
          "atc_class": "L",
          "atc_label": "Antineoplastic and Immunomodulating Agents"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_59132",
          "chebi_label": "monoclonal antibody",
          "go_id": "GO_0003823",
          "go_label": "antigen binding"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_017",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AIN457",
      "compound_code": "AIN457",
      "brand_name": "Cosentyx®",
      "indication": "Polymyalgia rheumatica",
      "therapeutic_area": "Immunology",
      "development_phase": "Phase 3",
      "compound_type": "Biologic",
      "mechanism_of_action": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2026",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AIN457",
        "brand_name": "Cosentyx®",
        "indication": "Polymyalgia rheumatica",
        "therapeutic_area": "Immunology",
        "phase": "Phase 3",
        "filing_date": "2026",
        "mechanism": "IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000540",
          "efo_label": "immune system disease",
          "mesh_id": "D007154",
          "mesh_label": "Immune System Diseases",
          "atc_class": "L",
          "atc_label": "Antineoplastic and Immunomodulating Agents"
        },
        "indication": {},
        "compound_type": {
          "chebi_id": "CHEBI_33695",
          "chebi_label": "biological macromolecule",
          "ncit_id": "C1909",
          "ncit_label": "Biological Products",
          "definition": "Large molecules produced by living organisms, including proteins, antibodies, and nucleic acids"
        },
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {
          "chebi_id": "CHEBI_59132",
          "chebi_label": "monoclonal antibody",
          "go_id": "GO_0003823",
          "go_label": "antigen binding"
        },
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_018",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "AMG334",
      "compound_code": "AMG334",
      "brand_name": "Aimovig®",
      "indication": "Migraine, pediatrics",
      "therapeutic_area": "Other/Emerging",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "CGRPR antagonist",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2027",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "AMG334",
        "brand_name": "Aimovig®",
        "indication": "Migraine, pediatrics",
        "therapeutic_area": "In-market Brands and Global Health",
        "phase": "Phase 3",
        "filing_date": "2027",
        "mechanism": "CGRPR antagonist"
      },
      "ontological_annotations": {
        "therapeutic_area": {},
        "indication": {},
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_019",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "BAF312",
      "compound_code": "BAF312",
      "brand_name": "Mayzent®",
      "indication": "Multiple sclerosis, pediatrics",
      "therapeutic_area": "Neuroscience",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "S1P1 Modulator (Sphingosine-1-phosphate receptor modulator)",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2027",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "BAF312",
        "brand_name": "Mayzent®",
        "indication": "Multiple sclerosis, pediatrics",
        "therapeutic_area": "Neuroscience",
        "phase": "Phase 3",
        "filing_date": "2027",
        "mechanism": "S1P1 Modulator (Sphingosine-1-phosphate receptor modulator)",
        "supplementary_indication": true
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000618",
          "efo_label": "nervous system disease",
          "mesh_id": "D009422",
          "mesh_label": "Nervous System Diseases",
          "atc_class": "N",
          "atc_label": "Nervous System"
        },
        "indication": {
          "mondo_id": "MONDO_0005301",
          "mondo_label": "multiple sclerosis",
          "mesh_id": "D009103",
          "mesh_label": "Multiple Sclerosis",
          "icd10": "G35",
          "snomed_ct": "24700007"
        },
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    },
    {
      "candidate_id": "NVS_020",
      "company": "Novartis",
      "company_code": "NVS",
      "compound_name": "BYL719",
      "compound_code": "BYL719",
      "brand_name": "Vijoyce®",
      "indication": "Lymphatic malformations",
      "therapeutic_area": "Oncology",
      "development_phase": "Phase 3",
      "compound_type": "Unknown",
      "mechanism_of_action": "PI3K-alpha inhibitor",
      "submission_type": null,
      "regulatory_designations": [],
      "filing_date": "2027",
      "lead_indication": false,
      "status": "Current",
      "source_data": {
        "compound": "BYL719",
        "brand_name": "Vijoyce®",
        "indication": "Lymphatic malformations",
        "therapeutic_area": "Oncology: Solid Tumors",
        "phase": "Phase 3",
        "filing_date": "2027",
        "mechanism": "PI3K-alpha inhibitor"
      },
      "ontological_annotations": {
        "therapeutic_area": {
          "efo_id": "EFO_0000616",
          "efo_label": "neoplasm",
          "mesh_id": "D009369",
          "mesh_label": "Neoplasms",
          "mondo_id": "MONDO_0004992",
          "mondo_label": "cancer",
          "atc_class": "L01",
          "atc_label": "Antineoplastic Agents"
        },
        "indication": {},
        "compound_type": {},
        "development_phase": {
          "ncit_id": "C15602",
          "ncit_label": "Phase III Trial",
          "definition": "Large-scale studies comparing new treatment to standard treatment"
        },
        "mechanism_of_action": {},
        "regulatory_designations": []
      }
    }
  ],
  "original_metadata": {
    "harmonization_date": "2025-07-03T20:30:52.186942",
    "version": "1.0",
    "description": "Harmonized pharmaceutical pipeline data from Novo Nordisk, Pfizer, and Novartis",
    "data_sources": [
      {
        "company": "novo_nordisk",
        "source_url": "https://www.novonordisk.com/science-and-technology/r-d-pipeline.html",
        "extraction_date": "2025-07-03"
      },
      {
        "company": "pfizer",
        "source_url": "https://www.pfizer.com/science/drug-product-pipeline",
        "extraction_date": "2025-07-03"
      },
      {
        "company": "novartis",
        "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
        "extraction_date": "2025-07-03"
      }
    ],
    "total_companies": 3,
    "total_candidates": 77
  },
  "companies": [
    {
      "company_name": "Novo Nordisk",
      "company_code": "NVO",
      "data_source": "https://www.novonordisk.com/science-and-technology/r-d-pipeline.html",
      "extraction_date": "2025-07-03",
      "pipeline_overview": {
        "description": "At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions. Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, cardiovascular disease, rare blood and endocrine disorders, and other serious chronic diseases.",
        "therapy_areas": [
          "Diabetes",
          "Obesity",
          "Cardiovascular Disease",
          "Emerging Therapy Areas",
          "Rare Blood Disorders",
          "Rare Endocrine Disorders"
        ],
        "development_phases": [
          "Phase 1",
          "Phase 2",
          "Phase 3",
          "Filed"
        ]
      },
      "total_candidates": 47,
      "phase_distribution": {
        "Phase 1": 19,
        "Phase 2": 13,
        "Phase 3": 10,
        "Registration/Filed": 5
      }
    },
    {
      "company_name": "Pfizer",
      "company_code": "PFE",
      "data_source": "https://www.pfizer.com/science/drug-product-pipeline",
      "extraction_date": "2025-07-03",
      "pipeline_overview": {
        "description": "We're in relentless pursuit of medicines and vaccines that will benefit patients around the world. Our ambitions are big and our product pipeline has never been stronger.",
        "areas_of_focus": [
          "Inflammation & Immunology",
          "Internal Medicine",
          "Oncology",
          "Vaccines"
        ],
        "development_phases": [
          "Phase 1",
          "Phase 2",
          "Phase 3",
          "Registration"
        ],
        "submission_types": [
          "New Molecular Entity",
          "Product Enhancement"
        ],
        "compound_types": [
          "Biologic",
          "Small Molecule",
          "Vaccine"
        ]
      },
      "total_candidates": 108,
      "phase_distribution": {
        "Phase 1": 47,
        "Phase 2": 28,
        "Phase 3": 30,
        "Registration/Filed": 3
      }
    },
    {
      "company_name": "Novartis",
      "company_code": "NVS",
      "data_source": "https://www.novartis.com/research-development/novartis-pipeline",
      "extraction_date": "2025-07-03",
      "pipeline_overview": {
        "description": "Benefiting from our continued focus on innovation, Novartis has one of the industry's most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide.",
        "therapeutic_areas": [
          "Oncology: Solid Tumors",
          "Oncology: Hematology",
          "Immunology",
          "Neuroscience",
          "In-market Brands and Global Health"
        ],
        "development_phases": [
          "Phase 1",
          "Phase 2",
          "Phase 3",
          "Registration"
        ]
      },
      "total_candidates": 20,
      "phase_distribution": {
        "Phase 1": 5,
        "Phase 2": 6,
        "Phase 3": 8,
        "Registration/Filed": 1
      }
    }
  ],
  "summary_statistics": {
    "total_candidates": 77,
    "by_company": {
      "Novo Nordisk": 47,
      "Pfizer": 10,
      "Novartis": 20
    },
    "by_phase": {
      "Phase 1": 34,
      "Phase 2": 19,
      "Phase 3": 18,
      "Registration/Filed": 6
    },
    "by_therapeutic_area": {
      "Diabetes": 12,
      "Obesity": 13,
      "Cardiovascular/Metabolic": 10,
      "Other/Emerging": 7,
      "Rare Diseases": 7,
      "Vaccines": 1,
      "Immunology": 7,
      "Oncology": 19,
      "Neuroscience": 1
    },
    "by_compound_type": {
      "Biologic": 19,
      "Unknown": 24,
      "Small Molecule": 15,
      "Cell Therapy": 2,
      "RNA Therapy": 2,
      "Vaccine": 1,
      "Radioligand": 14
    }
  }
}